About PathAI Products & Services

AI-Powered Drug Development & Diagnostics

Get more accurate and reproducible digital pathology analyses for each stage of your drug development process

Products & Services

We partner with biopharma across translational research, clinical trial execution, and diagnostic development

Translational Research

Identify new insights on pharmacodynamics, mechanism of action, and patient stratification

Recent Research & Case Studies

  • Work alongside a dedicated project team of pathologists and data scientists who bring  functional, scientific, and clinical expertise
  • Choose from available models across oncology, NASH, and other diseases; or build custom algorithms
  • Utilize PathAI’s in-house lab services for sample collection and digitization to accelerate sample processing timeline

Clinical Trial Services

Accurately quantify biomarkers for patient enrollment, endpoint analysis, and correlative studies in prospective clinical trials

  • Deploy AI algorithms at CROs or trial sites through PathAI’s analytically validated, GCP/GCLP compliant digital slide viewer
  • Receive patient- and lab-level reports on diagnosis, biomarker score, or other interpretable features
  • Utilize PathAI’s CLIA -certified lab services for end-to-end histopathology services in trials, including sample processing, staining, scanning, & digitization

Diagnostic Development & Deployment

Develop and commercialize AI-powered diagnostics globally and at scale

Our Approach:

  • Integrate AI algorithms into histology-based IVDs, including companion and complementary diagnostics
  • Engage health authorities and payers on regulatory submission and reimbursement with support from PathAI’s regulatory and medical affairs team
  • Launch diagnostics globally through PathAI’s US-based reference lab and its network of partner AP laboratories

See our latest case studies and publications


AI-based NASH scoring accurately reproduced all study endpoints for NASH resolution and highlighted more granular evidence of reduction in fibrosis


AI-powered PD-L1 scoring identified up to 28% additional PD-L1 positive patients that initially had been classified as PD-L1 negative by manual scoring in a retrospective analysis of a Phase 2b melanoma trial


AI-powered CD8 classification combined with PD-L1 status resulted in 40% increase in biomarker-positive patients vs. biomarker status based on PD-L1 expression alone in a retrospective analysis of a Phase 2b melanoma trial

Molecular Signatures

Trained AI models were shown to accurately predict HRD status from routine H&E-stained slides  

See how PathAI can help enhance your drug development